Skip to main content
. 2019 Sep 12;24:e00376. doi: 10.1016/j.btre.2019.e00376

Fig. 6.

Fig. 6

(a). Photo images of cytotoxicity activity against A549- C1 and HepG2-C2 cancer cell lines with (a) Untreated with cell (b) cell treated with standard drug (c) cell treated with rGO. (b). Shows the graphical representation of reduced graphene oxide (rGO) with different Concentration against A549 Human Lung Cancer Cell line and HepG2-Human Hepatocarcinoma Cell Line.